The association between tocilizumab and the secondary bloodstream infection maybe nonsignificant in hospitalized patients with SARS-CoV-2 infection: A cohort study

Background: Immunomodulatory agents, such as tocilizumab (TCZ), exert promising effects against SARS-CoV-2 infection. However, growing evidence indicates that using TCZ may carry higher risks of secondary bloodstream infection (sBSI). This study determined whether TCZ is associated with an increased...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	De-En Lu, Tsong-Yih Ou, Jyun-Wei Kang, Jie Ywi Ong, I-Ju Chen, Chih-Hsin Lee, Ming-Chia Lee
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2024-02-01
Cyfres:	Journal of Microbiology, Immunology and Infection
Pynciau:	SARS-CoV-2 infection Secondary bloodstream infections Tocilizumab
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S1684118223002025
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!